228. Bronchiolitis obliterans Clinical trials / Disease details
Clinical trials : 97 / Drugs : 118 - (DrugBank : 32) / Drug target genes : 33 - Drug target pathways : 156
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02181712 (ClinicalTrials.gov) | July 2014 | 2/7/2014 | Mesenchymal Stem Cell Therapy for Lung Rejection | A Pilot Study to Evaluate the Safety and Feasibility of Mesenchymal Stem Cells to Induce Remission in Lung Transplant Patients Experiencing Treatment-refractory Moderate to Severe Lung Rejection | Lung Transplant Reject;Bronchiolitis Obliterans | Biological: Mesenchymal stem cell 0.5;Biological: Mesenchymal stem cell 1.0 | Mayo Clinic | NULL | Completed | 18 Years | 75 Years | All | 19 | Phase 1 | United States |